KLTO Stock Down -34% after 8-Day Loss Streak
Klotho Neurosciences (KLTO) stock hit day 8 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -34% return. The company has lost about $5.7 Mil in value over the last 8 days, with its current market capitalization at about $17 Mil. The stock remains 0.0% above its value at the end of 2024. This compares with year-to-date returns of 10.2% for the S&P 500.
KLTO provides cell and gene therapies and biologics targeting neurological, age-related, and cancer disorders, partnering internationally to advance longevity and specialty diagnostics.
Comparing KLTO Stock Returns With The S&P 500
The following table summarizes the return for KLTO stock vs. the S&P 500 index over different periods, including the current streak:
- Is IVV’s Growth Engine Worth The Price Of Admission?
- Does Constellation Energy Stock’s Surge Broaden Your Portfolio Or Just Amplify It?
- Google Has The Best Problem Money Can’t Quite Buy
- How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story
- Who Really Powered VGT’s Climb This Year?
- Is The AI Super-Cycle Real Enough To Bet On Micron Stock?
| Return Period | KLTO | S&P 500 |
|---|---|---|
| 1D | -2.0% | -0.3% |
| 8D (Current Streak) | -35.7% | 0.7% |
| 1M (21D) | -49.0% | 2.2% |
| 3M (63D) | 148.6% | 9.1% |
| YTD 2025 | 0.0% | 10.2% |
| 2024 | -95.5% | 23.3% |
| 2023 | 6.3% | 24.2% |
| 2022 | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 88 S&P constituents with 3 days or more of consecutive gains and 23 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 69 | 10 |
| 4D | 8 | 6 |
| 5D | 7 | 6 |
| 6D | 3 | 1 |
| 7D or more | 1 | 0 |
| Total >=3 D | 88 | 23 |
Key Financials for Klotho Neurosciences (KLTO)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-0.6 Mil | $-5.5 Mil |
| Net Income | $-0.7 Mil | $-6.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-1.6 Mil | $-1.9 Mil |
| Net Income | $-2.2 Mil | $-4.1 Mil |
The losing streak KLTO stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.